Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study

Giovanna Orlando, Michela Fasolo, Francesca Mazza, Elena Ricci, Susanna Esposito, Elena Frati, Gian Vincenzo Zuccotti, Irene Cetin, Maria Gramegna, Giuliano Rizzardini, Elisabetta Tanzi, Maria Concetta Antonacci, Irene Arcidiacono, Silvia Bianchi, Veronica Boero, Giuseppe Cambiè, Elena Casolati, Valentina Montinaro, Marcella Falchetti, Marianna MartinelliCarlo Galli, Emanuela Bertazzoli, Giovanna Lunghi, Alberto Matteelli, Giancarlo Tisi, Anna Maria Villa, Nadia Zanchetta, Laura Pogliani

Research output: Contribution to journalArticle

Abstract

HPV vaccination is expected to reduce the incidence of cervical cancer. The greatest and the earliest health gains will be ensured by high vaccine coverage among all susceptible people. The high costs and the risk of a reduced cost/effectiveness ratio in sexually active girls still represent the main obstacles for a more widespread use of HPV vaccination in many countries. Data on the rate, risk factors, and HPV types in sexually active women could provide information for the evaluation of vaccination policies extended to broader age cohorts. Sexually active women aged 13-26 years enrolled in an Italian cohort study were screened for cervical HPV infections; HPV-DNA positive samples were genotyped by InnoLipa HPV Genotyping Extra or by RFLP genotype analysis. Among the 796 women meeting the inclusion criteria, 10.80% (95% CI 8.65-12.96) were HPV-DNA infected. Age >18 years, lifetime sexual partners >1, and history of STIs were associated to higher risk of HPV infection in the multivariable models adjusted for age, lifetime sexual partners, and time of sexual exposure. The global prevalence of the four HPV vaccine-types was 3.02% (95% CI 1.83-4.20) and the cumulative probability of infection from at least one vaccine-type was 12.82% in 26-years-old women and 0.78% in 18-years-old women. Our data confirm most of the previously reported findings on the risk factors for HPV infections. The low prevalence of the HPV vaccine-types found may be useful for the evaluation of the cost/efficacy and the cost/effectiveness of broader immunization programs beyond the 12-years-old cohort.

Original languageEnglish
Pages (from-to)986-994
Number of pages9
JournalHuman Vaccines and Immunotherapeutics
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 1 2014

Keywords

  • Hpv infection
  • Hpv vaccine
  • HR-HPV
  • Risk factors
  • Sexually active girls

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study'. Together they form a unique fingerprint.

  • Cite this

    Orlando, G., Fasolo, M., Mazza, F., Ricci, E., Esposito, S., Frati, E., Zuccotti, G. V., Cetin, I., Gramegna, M., Rizzardini, G., Tanzi, E., Antonacci, M. C., Arcidiacono, I., Bianchi, S., Boero, V., Cambiè, G., Casolati, E., Montinaro, V., Falchetti, M., ... Pogliani, L. (2014). Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study. Human Vaccines and Immunotherapeutics, 10(4), 986-994. https://doi.org/10.4161/hv.27682